Screener
Pfizer PFE Biopharma — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Pfizer’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000078003-26-000054
| (MILLIONS) | Three Months Ended / March 29,2026 | Three Months Ended / March 30,2025 |
|---|---|---|
| Biopharma reportable segment: | ||
| Biopharma total revenues | $14,161 | $13,441 |
| Less: | ||
| Cost of sales | 3,034 | 2,314 |
| Selling, informational and administrative expenses | 2,131 | 2,186 |
| Research and development expenses | 2,137 | 1,941 |
| Acquired in-process research and development expenses | 137 | 9 |
| Other (income)/deductions––net | (116) | (78) |
Item 1.
FAQ
- What is Pfizer's biopharma — cost of sales?
- Pfizer (PFE) reported biopharma — cost of sales of $3.03B in Q1 2026.
- How has Pfizer's biopharma — cost of sales changed year-over-year?
- Pfizer's biopharma — cost of sales increased by 31.1% year-over-year, from $2.31B to $3.03B.
- What is the long-term trend for Pfizer's biopharma — cost of sales?
- Over 3 years (2022 to 2025), Pfizer's biopharma — cost of sales has grown at a -25.7% compound annual growth rate (CAGR), from $32.86B to $13.51B.
- What does biopharma — cost of sales mean?
- The direct costs attributable to the production and distribution of the biopharma segment's products, including raw materials, manufacturing labor, and logistics. It is a key determinant of the segment's gross margin.
Ask your AI about Pfizer's biopharma — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude